Biographical Sketch
Michael A.Vogelbaum, MD, PhD, FACS, has been a member of the professional Staff in the Cleveland Clinic’s Department of Neurological Surgery since 1999. A graduate of the University of Virginia School of Medicine, Charlottesville, Va., he received his specialty training in neurosurgery at the Barnes-Jewish Hospital, St. Louis, Mo. He is board-certified in neurological surgery.
Specializing in the diagnosis and treatment of benign and malignant tumors of the brain and spinal cord, Dr. Vogelbaum also is interested in stereotactic (image-guided) surgery, Gamma Knife therapy and the molecular biology of brain tumors. He has joint appointments with the Cleveland Clinic Gamma Knife Center and the Lerner Research Institute’s Department of Cancer Biology. He is Associate Director of the Brain Tumor and NeuroOncology Center and Director of the Center for Translational Therapeutics at Cleveland Clinic.
In addition to his clinical duties, Dr. Vogelbaum is an active and enthusiastic Research Scientist. He was the recipient of the prestigious American Association of Neurological Surgeons Young Clinician Investigator Award, and receives support and funding from the American Cancer Society, the National Institutes of Health and the Wolf Family Foundation. He and the members of his research laboratory are presently investigating new approaches for the treatment of primary and metastatic brain tumors
Specialty Interests
benign and malignant tumors of the brain and spinal cord, gamma knife, molecular biology of brain tumors clinical and translational trials, stereotactic surgery, benign brain tumors (meningiomas, schwannomas), Brain Metastases, brain tumors, CNS metastatic disease, gamma knife and radiosurgery, Gamma Knife Radiosurgery, tumors of the brain and spine
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 7/30/2008, Dr.
Vogelbaum has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Vogelbaum receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
NeoPharm, Inc.
Schering-Plough Corporation
